GlassScriptPhysician profile
Dinh X Dam
NPI 1518936616
$4,848.98
in general payments reported to CMS, 2019-2025
14 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $301 · 2021: $1,001 · 2022: $381 · 2023: $541 · 2024: $998 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,156.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.05 | 2019-2021 | |
| Novo Nordisk INC | $501.05 | 2021-2025 | Ozempic |
| Glaxosmithkline, LLC. | $390.56 | 2022-2023 | Arexvy |
| Amgen INC. | $373.85 | 2024 | Otezla, Repatha |
| Boston Scientific Corporation | $302.64 | 2021-2022 | |
| Amarin Pharma, INC. | $232.72 | 2019 | |
| Silk Road Medical, INC. | $126.80 | 2021 | |
| Merck Sharp & Dohme LLC | $124.99 | 2020 | |
| Genentech USA, INC. | $30.60 | 2020 | |
| Pfizer INC. | $20.81 | 2025 | |
| Ibsa Pharma INC. | $19.14 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.34 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinh Dam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.